vs

Side-by-side financial comparison of Direct Digital Holdings, Inc. (DRCT) and Arcus Biosciences, Inc. (RCUS). Click either name above to swap in a different company.

Arcus Biosciences, Inc. is the larger business by last-quarter revenue ($11.0M vs $8.4M, roughly 1.3× Direct Digital Holdings, Inc.). Direct Digital Holdings, Inc. runs the higher net margin — -138.7% vs -963.6%, a 825.0% gap on every dollar of revenue. On growth, Direct Digital Holdings, Inc. posted the faster year-over-year revenue change (-7.4% vs -52.2%). Over the past eight quarters, Arcus Biosciences, Inc.'s revenue compounded faster (4.9% CAGR vs -38.6%).

Devolver Digital, Inc. is an American video game publisher based in Austin, Texas, specializing in the publishing of indie games. The company was founded in June 2009 by Nigel Lowrie, Harry Miller, Graeme Struthers, Rick Stults, and Mike Wilson, five executives who had been involved with Gathering of Developers and Gamecock Media Group, which published games on developer-friendly terms, but due to the high cost associated with releasing retail games saw themselves acquired and dissolved by la...

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

DRCT vs RCUS — Head-to-Head

Bigger by revenue
RCUS
RCUS
1.3× larger
RCUS
$11.0M
$8.4M
DRCT
Growing faster (revenue YoY)
DRCT
DRCT
+44.8% gap
DRCT
-7.4%
-52.2%
RCUS
Higher net margin
DRCT
DRCT
825.0% more per $
DRCT
-138.7%
-963.6%
RCUS
Faster 2-yr revenue CAGR
RCUS
RCUS
Annualised
RCUS
4.9%
-38.6%
DRCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DRCT
DRCT
RCUS
RCUS
Revenue
$8.4M
$11.0M
Net Profit
$-11.7M
$-106.0M
Gross Margin
26.8%
Operating Margin
-53.4%
-1036.4%
Net Margin
-138.7%
-963.6%
Revenue YoY
-7.4%
-52.2%
Net Profit YoY
-434.7%
-12.8%
EPS (diluted)
$-74.97
$-0.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DRCT
DRCT
RCUS
RCUS
Q4 25
$8.4M
$11.0M
Q3 25
$8.0M
$6.0M
Q2 25
$10.1M
$8.0M
Q1 25
$8.2M
$8.0M
Q4 24
$9.1M
$23.0M
Q3 24
$9.1M
$7.0M
Q2 24
$21.9M
$11.0M
Q1 24
$22.3M
$10.0M
Net Profit
DRCT
DRCT
RCUS
RCUS
Q4 25
$-11.7M
$-106.0M
Q3 25
$-2.7M
$-135.0M
Q2 25
$-2.2M
$0
Q1 25
$-2.4M
$-112.0M
Q4 24
$-2.2M
$-94.0M
Q3 24
$-2.7M
$-92.0M
Q2 24
$-590.0K
$-93.0M
Q1 24
$-775.0K
$-4.0M
Gross Margin
DRCT
DRCT
RCUS
RCUS
Q4 25
26.8%
Q3 25
27.7%
Q2 25
35.1%
Q1 25
29.3%
Q4 24
32.5%
Q3 24
38.7%
Q2 24
27.1%
Q1 24
22.4%
Operating Margin
DRCT
DRCT
RCUS
RCUS
Q4 25
-53.4%
-1036.4%
Q3 25
-49.0%
-2366.7%
Q2 25
-23.9%
-100.0%
Q1 25
-48.1%
-1525.0%
Q4 24
-51.8%
-447.8%
Q3 24
-40.3%
-1500.0%
Q2 24
-9.4%
-963.6%
Q1 24
-12.6%
-160.0%
Net Margin
DRCT
DRCT
RCUS
RCUS
Q4 25
-138.7%
-963.6%
Q3 25
-33.6%
-2250.0%
Q2 25
-22.2%
Q1 25
-28.9%
-1400.0%
Q4 24
-24.0%
-408.7%
Q3 24
-29.6%
-1314.3%
Q2 24
-2.7%
-845.5%
Q1 24
-3.5%
-40.0%
EPS (diluted)
DRCT
DRCT
RCUS
RCUS
Q4 25
$-74.97
$-0.88
Q3 25
$-0.24
$-1.27
Q2 25
$-0.23
$0.00
Q1 25
$-0.35
$-1.14
Q4 24
$-90.17
$-1.07
Q3 24
$-0.71
$-1.00
Q2 24
$-0.16
$-1.02
Q1 24
$-0.22
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DRCT
DRCT
RCUS
RCUS
Cash + ST InvestmentsLiquidity on hand
$728.0K
$222.0M
Total DebtLower is stronger
$99.0M
Stockholders' EquityBook value
$-7.0M
$631.0M
Total Assets
$20.2M
$1.1B
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DRCT
DRCT
RCUS
RCUS
Q4 25
$728.0K
$222.0M
Q3 25
$871.0K
$238.0M
Q2 25
$1.6M
$248.0M
Q1 25
$1.8M
$192.0M
Q4 24
$1.4M
$150.0M
Q3 24
$4.1M
$201.0M
Q2 24
$1.1M
$156.0M
Q1 24
$3.3M
$185.0M
Total Debt
DRCT
DRCT
RCUS
RCUS
Q4 25
$99.0M
Q3 25
$10.8M
$98.0M
Q2 25
$33.5M
$97.0M
Q1 25
$32.9M
$48.0M
Q4 24
$48.0M
Q3 24
$150.0K
$47.0M
Q2 24
$34.8M
Q1 24
$32.4M
Stockholders' Equity
DRCT
DRCT
RCUS
RCUS
Q4 25
$-7.0M
$631.0M
Q3 25
$-6.7M
$436.0M
Q2 25
$-24.6M
$549.0M
Q1 25
$-23.3M
$531.0M
Q4 24
$-19.7M
$485.0M
Q3 24
$-16.7M
$565.0M
Q2 24
$-10.5M
$635.0M
Q1 24
$-7.5M
$707.0M
Total Assets
DRCT
DRCT
RCUS
RCUS
Q4 25
$20.2M
$1.1B
Q3 25
$22.5M
$974.0M
Q2 25
$23.3M
$1.1B
Q1 25
$23.8M
$1.2B
Q4 24
$26.0M
$1.1B
Q3 24
$31.3M
$1.3B
Q2 24
$48.5M
$1.2B
Q1 24
$52.8M
$1.3B
Debt / Equity
DRCT
DRCT
RCUS
RCUS
Q4 25
0.16×
Q3 25
0.22×
Q2 25
0.18×
Q1 25
0.09×
Q4 24
0.10×
Q3 24
0.08×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DRCT
DRCT
RCUS
RCUS
Operating Cash FlowLast quarter
$-1.9M
$-120.0M
Free Cash FlowOCF − Capex
$-121.0M
FCF MarginFCF / Revenue
-1100.0%
Capex IntensityCapex / Revenue
9.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DRCT
DRCT
RCUS
RCUS
Q4 25
$-1.9M
$-120.0M
Q3 25
$-1.6M
$-97.0M
Q2 25
$-2.7M
$-133.0M
Q1 25
$-2.7M
$-132.0M
Q4 24
$-1.6M
$-100.0M
Q3 24
$3.0M
$26.0M
Q2 24
$-4.4M
$-94.0M
Q1 24
$-5.7M
$-2.0M
Free Cash Flow
DRCT
DRCT
RCUS
RCUS
Q4 25
$-121.0M
Q3 25
Q2 25
Q1 25
$-133.0M
Q4 24
$-101.0M
Q3 24
$25.0M
Q2 24
Q1 24
$-6.0M
FCF Margin
DRCT
DRCT
RCUS
RCUS
Q4 25
-1100.0%
Q3 25
Q2 25
Q1 25
-1662.5%
Q4 24
-439.1%
Q3 24
357.1%
Q2 24
Q1 24
-60.0%
Capex Intensity
DRCT
DRCT
RCUS
RCUS
Q4 25
9.1%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
12.5%
Q4 24
4.3%
Q3 24
14.3%
Q2 24
0.0%
Q1 24
40.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DRCT
DRCT

Buy Side Advertising$8.2M98%
Other$183.0K2%

RCUS
RCUS

Other$5.0M45%
Other Collaboration Revenue$4.0M36%
Access Rights And Option Continuation Periods$2.0M18%

Related Comparisons